Cancer NetworkOriginal article
<![CDATA[FDA Type C Meeting Granted for Pulmonary Metastatic Osteosarcoma Therapy]]>
RegulatoryOST-HER2Positive
AI Analysis
Summary
The FDA has granted a Type C meeting to discuss OST-HER2 for treating fully resected pulmonary metastatic osteosarcoma, based on 2.5-year overall survival data from a phase 2b trial.
Clinical Trial Data
Phase
2b
Primary Endpoint
Met
Outcome Details
Type C meeting granted by FDA
Importance:6/10
Sentiment:
0.60
regulatoryosteosarcomatype_c_meetingphase_2boncology
Read the original article
Published by Cancer Network on August 14, 2026 4:00 PM